This preprint is under consideration at Arthritis Research & Therapy. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: comparing the soluble receptor to monoclonal antibodies in a large observational cohort
Gisèle khoury
Hopital Lapeyronie
Corresponding Author
ORCiD: https://orcid.org/0000-0003-2766-9866
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The objective of this study was to compare in real life the occurrence of anterior uveitis in patients with spondyloarthritis (SpA), including psoriatic arthritis (PsA), treated with the soluble-receptor etanercept (ETA) or monoclonal antibodies (mAb).
Methods: This was an observational, retrolective study. Patients with SpA who were prescribed anti-TNF agents between 2000 and 2014 were included. The risk of uveitis was interpreted qualitatively (number of subjects with at least one uveitis) and quantitatively (number of uveitis flares for each individual). Models were adjusted for propensity score of receiving preferentially mAbs or ETA.
Results: 429 patients were included (302 with SpA and 127 with PsA); 203 received a mAb and 226 ETA as a first TNF-a inhibitor. Probability of uveitis occurring during the first year of treatment was lower with ETA than mAbs but not significantly (odds ratio 0.94 [95% confidence interval 0.35; 2.54], p=0.90, on qualitative analysis and relative risk 0.62 [0.26; 1.46], p=0.27, on quantitative analysis) after adjustment for the propensity score. The over-time risk of uveitis was numerically higher with ETA than mAbs, but the differences were not statistically significant.
Conclusion: In this observational study, the risk of uveitis in patients with SpA does not appear to be greater with ETA than mAbs treatment. The occurrence of uveitis in patients receiving an anti-TNF-a agent seems linked more to history of uveitis than the prescribed molecule.
Keywords
spondyloarthritis, psoriatic arthritis, uveitis, TNF inhibitors
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 3
Posted 17 Apr, 2020
No community comments so far
Editor assigned
On 13 Apr, 2020
Reviewers invited
Invitations sent on 13 Apr, 2020
Reviewer #1 agreed
On 13 Apr, 2020
Reviewer #2 agreed
On 13 Apr, 2020
Review #2 received
Received 13 Apr, 2020
Review #1 received
Received 13 Apr, 2020
Submission checks complete
On 12 Apr, 2020
Editor invited
On 12 Apr, 2020
No comments provided
Editorial decision: Major revision
On 09 Apr, 2020
Review #2 received
Received 08 Apr, 2020
Review #1 received
Received 07 Apr, 2020
Editor assigned
On 03 Apr, 2020
Reviewers invited
Invitations sent on 03 Apr, 2020
Reviewer #1 agreed
On 03 Apr, 2020
Reviewer #2 agreed
On 03 Apr, 2020
Submission checks complete
On 02 Apr, 2020
Editor invited
On 02 Apr, 2020
No comments provided
Review #1 received
Received 29 Feb, 2020
Editorial decision: Major revision
On 29 Feb, 2020
Review #2 received
Received 28 Feb, 2020
Reviewer #2 agreed
On 15 Feb, 2020
Reviewer #1 agreed
On 14 Feb, 2020
Reviewers invited
Invitations sent on 13 Feb, 2020
Editor assigned
On 12 Feb, 2020
Submission checks complete
On 11 Feb, 2020
Editor invited
On 11 Feb, 2020
First submitted
On 10 Feb, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Rheumatology
Learn more about our company.
This preprint is under consideration at Arthritis Research & Therapy. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: comparing the soluble receptor to monoclonal antibodies in a large observational cohort
Gisèle khoury
Hopital Lapeyronie
Corresponding Author
ORCiD: https://orcid.org/0000-0003-2766-9866
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 3
Posted 17 Apr, 2020
No community comments so far
Editor assigned
On 13 Apr, 2020
Reviewers invited
Invitations sent on 13 Apr, 2020
Reviewer #1 agreed
On 13 Apr, 2020
Reviewer #2 agreed
On 13 Apr, 2020
Review #2 received
Received 13 Apr, 2020
Review #1 received
Received 13 Apr, 2020
Submission checks complete
On 12 Apr, 2020
Editor invited
On 12 Apr, 2020
No comments provided
Editorial decision: Major revision
On 09 Apr, 2020
Review #2 received
Received 08 Apr, 2020
Review #1 received
Received 07 Apr, 2020
Editor assigned
On 03 Apr, 2020
Reviewers invited
Invitations sent on 03 Apr, 2020
Reviewer #1 agreed
On 03 Apr, 2020
Reviewer #2 agreed
On 03 Apr, 2020
Submission checks complete
On 02 Apr, 2020
Editor invited
On 02 Apr, 2020
No comments provided
Review #1 received
Received 29 Feb, 2020
Editorial decision: Major revision
On 29 Feb, 2020
Review #2 received
Received 28 Feb, 2020
Reviewer #2 agreed
On 15 Feb, 2020
Reviewer #1 agreed
On 14 Feb, 2020
Reviewers invited
Invitations sent on 13 Feb, 2020
Editor assigned
On 12 Feb, 2020
Submission checks complete
On 11 Feb, 2020
Editor invited
On 11 Feb, 2020
First submitted
On 10 Feb, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Rheumatology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The objective of this study was to compare in real life the occurrence of anterior uveitis in patients with spondyloarthritis (SpA), including psoriatic arthritis (PsA), treated with the soluble-receptor etanercept (ETA) or monoclonal antibodies (mAb).
Methods: This was an observational, retrolective study. Patients with SpA who were prescribed anti-TNF agents between 2000 and 2014 were included. The risk of uveitis was interpreted qualitatively (number of subjects with at least one uveitis) and quantitatively (number of uveitis flares for each individual). Models were adjusted for propensity score of receiving preferentially mAbs or ETA.
Results: 429 patients were included (302 with SpA and 127 with PsA); 203 received a mAb and 226 ETA as a first TNF-a inhibitor. Probability of uveitis occurring during the first year of treatment was lower with ETA than mAbs but not significantly (odds ratio 0.94 [95% confidence interval 0.35; 2.54], p=0.90, on qualitative analysis and relative risk 0.62 [0.26; 1.46], p=0.27, on quantitative analysis) after adjustment for the propensity score. The over-time risk of uveitis was numerically higher with ETA than mAbs, but the differences were not statistically significant.
Conclusion: In this observational study, the risk of uveitis in patients with SpA does not appear to be greater with ETA than mAbs treatment. The occurrence of uveitis in patients receiving an anti-TNF-a agent seems linked more to history of uveitis than the prescribed molecule.
Figure 1